Prolactinoma natural history, complications, and prognosis: Difference between revisions
Undo revision 739552 by Raviteja Reddy Guddeti (talk) |
No edit summary |
||
| Line 26: | Line 26: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Neuroendocrinology]] | [[Category:Neuroendocrinology]] | ||
[[Category:Mature chapter]] | [[Category:Mature chapter]] | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
Revision as of 19:20, 27 August 2015
|
Prolactinoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Prolactinoma natural history, complications, and prognosis On the Web |
|
American Roentgen Ray Society Images of Prolactinoma natural history, complications, and prognosis |
|
FDA on Prolactinoma natural history, complications, and prognosis |
|
CDC on Prolactinoma natural history, complications, and prognosis |
|
Prolactinoma natural history, complications, and prognosis in the news |
|
Blogs on Prolactinoma natural history, complications, and prognosis |
|
Risk calculators and risk factors for Prolactinoma natural history, complications, and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
Natural History
Complications
Osteoporosis Risk
Hyperprolactinemia can cause reduced estrogen production in women and reduced testosterone production in men. Although estrogen/testosterone production may be restored after treatment for hyperprolactinemia, even a year or two without estrogen/testosterone can compromise bone strength, and patients should protect themselves from osteoporosis by increasing exercise and calcium intake through diet or supplementation, and by avoiding smoking. Patients may want to have bone density measurements to assess the effect of estrogen/testosterone deficiency on bone density. They may also want to discuss testosterone/estrogen replacement therapy with their physician.
Prognosis
People with microprolactinoma generally have an excellent prognosis. In 95% of cases the tumor will not show any signs of growth after a 4 to 6 year period.
Macroprolactinomas often require more aggressive treatment otherwise they may continue to grow. There is no way to reliably predict the rate of growth, as it is different for every individual. Regular monitoring by a specialist to detect any major changes in the tumor is recommended.